Literature DB >> 326072

Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine.

D F Clyde, V C McCarthy.   

Abstract

Glucose-6-phosphate dehydrogenase-normal adult volunteers infected with mosquito-bone Chesson strain vivax malaria were treated with chloroquine and primaquine during the initial attack. Administration of 60 mg (base) of primaquine daily for 7 days was as effective in preventing relapse as is the regimen customarily used for the radical cure of infections produced by this strain, namely, 30 mg daily for 14 days. However, it is stressed that because of the risk of primaquine-induced hemolysis in individuals having genetically-transmitted erythrocyte abnormalities this high dosage should not be used routinely.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326072     DOI: 10.4269/ajtmh.1977.26.562

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

Review 1.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

2.  Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.

Authors:  Salomón Durand; Cesar Cabezas; Andres G Lescano; Mariela Galvez; Sonia Gutierrez; Nancy Arrospide; Carlos Alvarez; Meddly L Santolalla; David J Bacon; Paul C F Graf
Journal:  Am J Trop Med Hyg       Date:  2014-04-21       Impact factor: 2.345

3.  Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys.

Authors:  L H Schmidt
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Plasmodium vivax polymorphism in a clinical drug trial.

Authors:  T Adak; N Valecha; V P Sharma
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

5.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Authors:  A Ratcliff; H Siswantoro; E Kenangalem; R Maristela; R M Wuwung; F Laihad; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

6.  Usefulness of seminested multiplex PCR in surveillance of imported malaria in Spain.

Authors:  J M Rubio; A Benito; P J Berzosa; J Roche; S Puente; M Subirats; R López-Vélez; L García; J Alvar
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

7.  Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug.

Authors:  D F Clyde
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

Review 8.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

9.  Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers.

Authors:  L H Schmidt; S Alexander; L Allen; J Rasco
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

10.  Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia.

Authors:  Guang-Sheng Lei; Chen Zhang; Michelle K Zimmerman; Chao-Hung Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.